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Abstract: BACKGROUND Patients experiencing acute lung injury (ALI) often need mechanical ven-
tilation for which sedation may be required. In such patients, usually the first choice an intravenously
administered drug. However, growing evidence suggests that volatile anesthetics such as sevoflurane are
a valuable alternative. In this study, we evaluate pulmonary and systemic effects of long-term (24-hour)
sedation with sevoflurane compared with propofol in an in vivo animal model of ALI. METHODS Adult
male Wistar rats were subjected to ALI by intratracheal lipopolysaccharide (LPS) application, mechan-
ically ventilated and sedated for varying intervals up to 24 hours with either sevoflurane or propofol.
Vital parameters were monitored, and arterial blood gases were analyzed. Inflammation was assessed
by the analysis of bronchoalveolar lavage fluid (BALF), cytokines (monocyte chemoattractant protein-1
[MCP-1], cytokine-induced neutrophil chemoattractant protein-1 [CINC-1], interleukin [IL-6], IL-12/12a,
transforming growth factor-￿, and IL-10) in blood and lung tissue and inflammatory cells. The alve-
olocapillary barrier was indirectly assessed by wet-to-dry ratio, albumin, and total protein content in
BALF. Results are presented as mean ± standard deviation. RESULTS After 9 hours of ventilation and
sedation, oxygenation index was higher in the LPS/sevoflurane (LPS-S) than in the LPS/propofol group
(LPS-P) and reached 400 ± 67 versus 262 ± 57 mm Hg after 24 hours (P < .001). Cell count in BALF in
sevoflurane-treated animals was lower after 18 hours (P = .001) and 24 hours (P < .001) than in propofol
controls. Peak values of CINC-1 and IL-6 in BALF were lower in LPS-S versus LPS-P animals (CINC-1:
2.7 ± 0.7 vs 4.0 ± 0.9 ng/mL; IL-6: 9.2 ± 2.3 vs 18.9 ± 7.1 pg/mL, both P < .001), whereas IL-10
and MCP-1 did not differ. Also messenger RNAs of CINC-1, IL-6, IL-12a, and IL-10 were significantly
higher in LPS-P compared with LPS-S. MCP-1 and transforming growth factor-￿ showed no differences.
Wet-to-dry ratio was lower in LPS-S (5.4 ± 0.2 vs 5.7 ± 0.2, P = .016). Total protein in BALF did not
differ between P-LPS and S-LPS groups. CONCLUSIONS Long-term sedation with sevoflurane com-
pared with propofol improves oxygenation and attenuates the inflammatory response in LPS-induced
ALI. Our findings suggest that sevoflurane may improve lung function when used for sedation in patients
with ALI.
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Acute lung injury (ALI) frequently requires both mechanical ventilation and sedation in the intensive care unit (ICU).1,2 Currently, approximately 10% of 
patients treated in the ICU experience ALI or acute respira-
tory distress syndrome (ARDS),3 and mortality rates of up 
to 50% have been described.4 Immune activation and a mas-
sive release of proinflammatory mediators are hallmarks of 
ALI and ARDS,5 and mechanical ventilation may further 
exacerbate the inflammatory response.6–8 Cytokines recruit 
effector cells, which amplify the inflammatory response.9
Bacterial lipopolysaccharides (LPSs) are complex glyco-
lipids found on the outer membrane of Gram-negative bac-
teria10 and have been utilized to examine in vitro and in vivo 
inflammatory responses.10–12 Other markers of ALI include 
endothelial barrier disruption, recruitment and transmigra-
tion of neutrophils, and development of a protein- and neu-
trophil-rich (noncardiogenic) pulmonary edema.13–16
According to current guidelines, intravenous propofol, 
midazolam, and dexmedetomidine are recommended for 
sustained sedation in critically ill patients.17,18 However, 
since the introduction of the Anaesthetic Conserving Device 
(AnaConDa; Sedana Medical AB, Uppsala, Sweden), ICU 
sedation may also be possible with volatile anesthetics such 
as isoflurane or sevoflurane.19 When compared with intra-
venous sedation, volatile sedation has been associated with 
shorter weaning times,20 less ICU and hospital days,21 and 
no difference in safety.20,22,23
The anti-inflammatory properties of volatile anesthet-
ics have been demonstrated in experimental (LPS-induced) 
lung injury.12 However, little is known about the impact 
of sedatives on the course of ALI during mechanical 
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ventilation. We thus evaluated the effect of 2 sedative agents 
(sevoflurane or propofol) on pulmonary inflammation and 
lung function in ventilated and sedated rats with ALI for up 
to 24 hours. We hypothesized that sedation with sevoflu-
rane would result in better oxygenation and less inflamma-
tion when compared with propofol.
METHODS
Animals
Adult male Wistar rats (Charles River, Sulzfeld, Germany; 
364 ± 28 g) were used in this experiment (protocol approved 
by the veterinarian authorities, Veterinäramt Zürich, 
Switzerland, No. 94/2013). Animals were housed in stan-
dard cages at 22°C (±1°C), a 12-/12-hour light/dark cycle, 
and free access to food and water.
Animal Preparation
Anesthesia was induced with 100 mg/kg body weight (BW) 
thiopental (Pentothal; Inresa, Freiburg, Switzerland) intra-
peritoneally. Sterile polyethylene catheters were placed into 
the left jugular vein for fluid (Ringer’s lactate, Ri-Lac; B. 
Braun, Sempach, Switzerland) and propofol administration 
(Disoprivan 2%; AstraZeneca, Zug, Switzerland) and into 
the right carotid artery for pressure monitoring and arterial 
blood gas analyses (aBGA). Oxygen saturation was recorded 
using pulse oximetry. After tracheotomy, rats were mechan-
ically ventilated (Servo Ventilator 300; Maquet, Solna, 
Sweden) with or without sevoflurane (Sevorane; AbbVie 
AG, Baar, Switzerland). The ventilator was set to a peak 
inspiratory pressure of 14 cm H2O, a positive end-expira-
tory pressure of 3 cm H2O, an inspiratory fraction of oxygen 
(Fio2) starting at 0.6, and a respiratory rate of 30 breaths/
min. Respiratory rate and Fio2 were adjusted according 
to aBGAs (targets: Pco2 35–50 mm Hg, Po2 >100 mm Hg, 
and pH 7.35–7.45; a maximum Fio2 of 0.7 was used in our 
setting). Normal body temperature was maintained by the 
use of a heating pad with a feedback control system.
Assignment to Groups and Sedation Procedure
Groups of 2 animals were sedated for 6, 12, 18, or 24 hours 
before analysis (Figure 1) and randomly assigned to the fol-
lowing groups:
1. PBS-P (n = 16): pulmonary phosphate-buffered saline 
(PBS) instillation, propofol sedation
2. LPS-P (n = 24): LPS instillation, propofol sedation
3. PBS-S (n = 16): PBS instillation, sevoflurane sedation
4. LPS-S (n = 24): LPS instillation, sevoflurane sedation
Animals were sedated with 10 mg/kg BW/h propofol 
(PBS-P and LPS-P) or with 0.5 minimum alveolar concentra-
tion (approximately 1.3 vol%) sevoflurane (PBS-S and LPS-S 
groups). The dose of the 2 anesthetics was adjusted accord-
ing to the blood pressure in animals (mean arterial pressure 
[MAP] target range: 60–80 mm Hg). For estimation of seda-
tion depth, we defined rapid MAP peaks in combination 
with heart rate step-ups as a sign of insufficient or even plain 
level of anesthesia. In addition, whisker movement was seen 
when anesthesia was too low. In conclusion, continuous pro-
pofol or sevoflurane administration was increased.
Further information about the hemodynamic and anal-
gesic management is provided in Supplemental Digital 
Content, Supplements S1 and S2 (http://links.lww.com/
AA/B478; http://links.lww.com/AA/B479).
Induction of ALI
Twenty minutes after anesthesia induction, 0.3 µg/g BW 
LPS (Escherichia coli—LPS, serotype 055:B5; Sigma-Aldrich, 
Buchs, Switzerland) diluted in 300 µL PBS (Gibco, Paisley, 
UK) was applied intratracheally using a fine polyethylene 
tube (ID 0.58 mm; Smiths Medical International Ltd., Kent, 
UK). Control groups received 300 µL PBS only.
Collecting of Samples
aBGAs were performed before LPS or PBS instillation and 
every 3 hours subsequently until the end of the experiment. 
Whole blood was heparinized and allowed to sit for 5 min-
utes before being centrifuged (1250 relative centrifugal force 
[rcf], 4°C). For bronchoalveolar lavage, the right lung was 3 
times flushed with 5 mL PBS. The collected fluid (bronchoal-
veolar lavage fluid [BALF]) was centrifuged (1250 rcf, 4°C). 
Cell pellets were resuspended in 1 mL PBS.
Snap frozen lungs, plasma, and BALF were stored at 
−80°C. In animals assigned for the determination of lung 
permeability, no bronchoalveolar lavage was performed.
Alveolocapillary Integrity
Oxygenation index (Horowitz index) was calculated using 
the quotient of arterial partial pressure (in mm Hg) and inspi-
ratory fraction of oxygen in the ventilated lungs (PaO2/Fio2).
Total protein in BALF was measured using the dDC 
Protein Assay (Bio-Rad Laboratories, Hercules, CA) in 
accordance with the manufacturer’s instructions. Albumin 
in BALF was determined by enzyme-linked immunosor-
bent assay (ELISA; Bethyl Laboratories Inc., Montgomery, 
TX) in accordance with the manufacturer’s protocol.
Figure 1. Experimental setup. After an initial 
i.p. sedation using thiopental for preparation 
of animals, acute lung injury was induced by 
intratracheal installation of lipopolysaccharide 
(LPS). Control animals, sedated with propofol 
or sevoflurane, were treated with phosphate-
buffered saline, PBS) instead of LPS.
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Lungs of animals sedated for 12 hours and stimulated 
with LPS were weighed immediately after removal and 
after 72 hours of drying at 65°C. The quotient of (lung wet 
weight)/(lung dry weight) was determined.
Inflammatory Cells in ALI
Resuspended cells of BALF were dyed with trypan blue and 
quantified with a Neubauer Chamber (C-Chip Neubauer 
Improved; Digital Bio, Pleasanton, CA). Cell differentiation 
is given in the Supplemental Digital Content, Supplement 
S3 (http://links.lww.com/AA/B480).
Inflammatory Cytokines
Sandwich ELISAs for monocyte chemoattractant protein-1 
(MCP-1), cytokine-induced neutrophil chemoattractant 
protein-1 (CINC-1), interleukin-6 (IL-6), IL-12, and anti-
inflammatory protein IL-10 were performed in accordance 
with the manufacturer’s protocol to assess inflammatory 
responses in BALF and in plasma. Details are shown in 
the Supplemental Digital Content, Supplement S4 (http://
links.lww.com/AA/B481).
Messenger RNA of Cytokines
Total RNA for the determination of MCP-1, CINC-1, IL-6, 
IL-12a, transforming growth factor-β, and IL-10 was iso-
lated from lung tissue.
Detailed procedures, primers, and TaqMan probes are 
declared in the Table and the Supplemental Digital Content, 
Supplement S5 (http://links.lww.com/AA/B482).
Renal Function
Because of its metabolites, the long-term use of sevoflu-
rane could result in renal disturbances and damages.24 To 
address this question, we recorded urine output, total fluid 
administration, and net fluid balance of animals sedated 
for 24  hours in addition to the specific functional renal 
parameters creatinine in plasma and neutrophil gelatinase-
associated lipocalin (NGAL) in urine. Details of the meth-
ods and kits can be found in Supplemental Digital Content, 
Supplement S6 (http://links.lww.com/AA/B483).
Statistical Analysis
Based on an effect size of f2 = 0.15, an α value of .05, and a 
power of 80% in addition to 3 predictors: time, LPS/PBS 
and sevoflurane/propofol, and power analysis, revealed 
the inclusion of 80 animals.
Statistical analyses were performed in GraphPad Prism 
6 (GraphPad Software Inc., La Jolla, CA) and Program R 
(R Foundation for Statistical Computing, Vienna, Austria). 
Data are presented as mean ± standard deviation. For non-
repeated measurements, 2-way analysis of variance was per-
formed, and multiple comparisons were corrected for by the 
Tukey post hoc test.
Repeated measurements and comparison of experi-
ments with different duration, linear mixed-effects models 
were used with PBS-P as the reference group. We applied 
linear mixed-effects models including the interaction term 
between time and group (no intercept) using the lme4 pack-
age. To test for time-specific group effects (testing for differ-
ences among groups at each time point), we subsequently 
applied a Dunnett post hoc test controlled for multiple test-
ing using the generalized linear hypothesis test (glht) in the 
multcomp package. Specifically, linear mixed models were 
used for the analysis of hemodynamic stability measure-
ments, continuous Ringer’s lactate application, cumulative 
Ringer’s lactate boluses, and for continuous norepinephrine 
application.
Wet-to-dry weight differences were assessed by Mann-
Whitney U test (group size of 5 animals); the exact P value 
was computed (GraphPad Prism).
P < .05 was considered significant for Mann-Whitney U 
test and for linear mixed models. For Tukey-corrected anal-
ysis of variance, P < .01 was considered significant. The 99% 
Tukey-corrected confidence intervals (99% CIs) were used.
RESULTS
Blood Oxygenation
Blood oxygenation decreased in both LPS groups over time, 
but the decrease was more pronounced in propofol ani-
mals. After 9 hours of injury, differences between LPS-P and 
LPS-S animals were observed (412 ± 70 vs 468 ± 34 mm Hg; 
99% CI, −106 to −5 mm Hg; P = .004) that persisted at 
24 hours (262 ± 57 vs 400 ± 67 mm Hg; 99% CI, −224 to 
−52 mm Hg; P < .001; Figure 2).
Fio2 was adjusted in 5 animals in the LPS-P and in 2 ani-
mals in the LPS-S group. The maximal Fio2 was 0.7 in the 
LPS-P and 0.65 in the LPS-S group.
Table. Real-Time Quantitative TaqMan PCR—Used 
Primers and Probes
Gene Primer Sequence
Length of 
Amplicon, 
nt
IL-12a
  Up 5′ CCT GCC AAG TGT CTT AAC CAG 3′ 95
  Down 5′ GTG CAA GAG TAA TGT TTC AAT TTC TC 3′
  Probe 62 5′ ACC TGC TG 3′
IL-10
  Up 5′ CAG ATT CCT TAC TGC AGG ACT TTA 3′ 128
  Down 5′ CAA ATG CTC CTT GAT TTC TGG 3′
  Probe 13 5′ AGG CAG AG 3′
IL-6
  Up 5′ CCC TTC AGG AAC AGC TAT GAA 3′ 74
  Down 5′ ACA ACA TCA GTC CCA AGA AGG 3′
  Probe 20 5′ CTG GCT GG 3′
CINC-1
  Up 5′ CAC ACT CCA ACA GAG CAC CA 3′ 120
  Down 5′ TGA CAG CGC AGC TCA TTG 3′
  Probe 49 5′ CAG CCA CC 3′
MCP-1
  Up 5′ AGC ATC CAC GTG CTG TCT C 3′ 78
  Down 5′ GAT CAT CTT GCC AGT GAA TGA GT 3′
  Probe 62 5′ ACC TGC TG 3′
TGF-β
  Up 5′ AAG GGC TAC CAT GCC AAC TT 3′ 92
  Down 5′ TGG TTG TAG AGG GCA AGG AC 3′
  Probe 116 5′ GAG CCT GG 3′
18S
  Up 5′ AAT CAG TTA TGG TTC CTT TGT CG 3′ 65
  Down 5′ GCT CTA GAA TTA CCA CAG TTA TCC AA 3′
  Probe 55 5′ TCC TCT CC 3′
Abbreviations: 18S, housekeeping gene; CINC-1, cytokine-induced neutrophil 
chemoattractant-1; IL-6, interleukin 6; IL-10, interleukin 10; IL-12a, interleukin 
12a; MCP-1, monocyte chemoattractant protein-1; nt, nucleotides; PCR, 
polymerase chain reaction; TGF-β, transforming growth factor beta.
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Impairment of the Alveolocapillary Barrier
For the determination of lung wet-to-dry weight ratio, the 
time point of 12 hours was chosen because of the difference 
in oxygenation we observed. The wet-to-dry ratio of LPS-P 
was higher compared with LPS-S animals (5.7 ± 0.2 vs 5.4 ± 
0.2; P = .016; Figure 3A).
To further explore the effect of anesthetic agent on the 
integrity of the alveolocapillary barrier, we measured total 
protein levels in BALF. When compared with propofol, sevo-
flurane had a nonsignificant effect on total protein in LPS-
treated rats (1.5 vs 0.7 mg/mL; 99% CI, −0.1 to 1.7 mg/mL; 
P =  .028, nonsignificant; Figure 3B). A similar pattern was 
observed for albumin concentrations in BALF (Figure 3C).
Cells in BALF increased over time in all LPS groups. 
After 18 hours, we found 44 ± 5 versus 28 ± 10 × 106 cells/
mL BALF and after 24 hours 50 ± 14 versus 28 ± 7 × 106 
cells/mL in LPS-P-treated versus LPS-S-treated animals, 
respectively (18 hours: 99% CI, 2.7 to 29.4 × 106 cells/
mL; P = .001; 24 hours: 99% CI, 8.5 to 35.2 × 106 cells/mL; 
P < .001; Figure 3D).
Differential analysis of the cell types found in BALF 
revealed a higher count of neutrophils in LPS-P versus 
LPS-S (18 hours: 41 ± 4 vs 26 ± 11 × 106 cells/mL BALF; 99% 
CI, 1 to 29 × 106 cells/mL; P = .006; 24 hours: 47 ± 13 vs 25 
± 7 × 106 cells/mL BALF; 99% CI, 9 to 36 × 106 cells/mL; 
P < .001). No difference could be found for the subpopula-
tions of macrophages, lymphocytes, or erythrocytes (P = .41, 
P = .77, and P = .99, respectively, at 24 hours).
Figure 2. Oxygenation index (Horowitz). Oxygenation index in 
ventilated rats subjected to acute lung injury by intratracheal 
lipopolysaccharide (LPS) application. Control animals received phos-
phate-buffered saline (PBS). Animals were sedated with propofol (-P) 
or sevoflurane (-S) for up to 24 hours. Values are expressed as 
mean ± SD. *P = .004, †P ≤ .001 LPS-P versus LPS-S at the cor-
responding time point; ‡P = .004 LPS-S versus PBS-S at 24 hours. 
Fio2, inspiratory fraction of oxygen.
Figure 3. A–D, Determination of integrity of the alveolocapillary barrier. The alveolocapillary barrier was evaluated by the determination of 
total protein content (B) and albumin (C) in bronchoalveolar lavage fluid (BALF) obtained from ventilated rats subjected to acute lung injury 
(ALI) by intratracheal lipopolysaccharide (LPS) application (control animals received phosphate-buffered saline [PBS]). Animals were sedated 
with propofol (-P) or sevoflurane (-S) for up to 24 hours. In addition, total cell count in BALF (D) and lung wet-to-dry-ratio (W/D ratio, A) were 
assessed. Values are expressed as mean ± SD. †P = .001, ‡P < .001 LPS-P versus LPS-S at the corresponding time point.
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Inflammation in the Respiratory Compartment
Twelve hours after LPS administration, MCP-1 concentra-
tions were higher in both LPS-P and LPS-S groups compared 
with their respective controls. At 12 hours, a significant 
injury-induced increase of MCP-1 was observed (PBS-P 
versus LPS-P: 10 ± 11 versus 212 ± 148 ng/mL, 99% CI, −374 
to −30, P < .001, and PBS-S versus LPS-S: 6 ± 2 versus 216 ± 
182 ng/mL, 99% CI, −382 to −37, P = .001). Values did not 
differ between rats sedated with propofol or sevoflurane (P 
= 1.0). At 18 hours, MCP-1 concentrations were again not 
different between LPS-P versus LPS-S animals (246 ± 150 vs 
218 ± 73 ng/mL, respectively; 99% CI, −125 to 183 ng/mL; 
P = .9; Figure 4A).
At 6 hours, CINC-1 values measured in BALF were higher 
in LPS-P than in LPS-S animals (4.0 ± 0.9 vs 2.7 ± 0.7 ng/mL, 
respectively; 99% CI, 0.4 to 2.3 ng/mL, P < .001; Figure 4B).
IL-6 concentrations in BALF at 6 hours were also higher 
in LPS-P than in LPS-S animals (18.9 ± 7.1 vs 9.2±2.3 ng/mL; 
99% CI, 5.3 to 14.0 ng/mL; P < .001; Figure 4C). No differ-
ences were found at later time points (P = .31, .99, and .71 at 
12, 18, and 24 hours).
IL-12 was below detection range in all groups at all time 
points. IL-10 concentrations in BALF did not differ at any 
time point between LPS-S and LPS-P groups (P = .56, .27, .35, 
and .90 at 6, 12, 18, and 24 hours, respectively; Figure 4D).
Inflammation in the Interstitial Compartment
The messenger RNA (mRNA) expression pattern for the pro-
inflammatory cytokines MCP-1, CINC-1, IL-6, and IL-12a in 
lung tissue was similar (Figure 5, A–D). Although no dif-
ference between LPS-P and LPS-S was found at 6 hours for 
MCP-1 mRNA, CINC-1 mRNA values were higher in the 
LPS-P than in the LPS-S group (91 ± 33 vs 66 ± 16; 99% CI, 6 
to 45; P < .001). Similarly, IL-6 mRNA expression was higher 
in LPS-P than in LPS-S animals at 6 hours (1483 ± 338 vs 923 
± 353; 99% CI, 309 to 812; P < .001) as were IL-12a mRNA 
values (4.3 ± 1.4 vs 2.6 ± 0.4; 99% CI, 0.9 to 2.7; P < .001). For 
transforming growth factor-β, the 2 sedative groups did not 
differ (Figure 5E).
IL-10 mRNA was clearly upregulated in the LPS-P group 
compared with LPS-S animals (6 hours: 41 ± 15 vs 23 ± 10; 
99% CI, 3 to 33; P = 0.001; Figure 5F).
Systemic Inflammation
With our sample size, we did not detect a significant dif-
ference between LPS-P and LPS-S in plasma MCP-1 levels 
(6 hours: 429.9 ± 139.6 vs 343.6 ± 112.7 ng/mL; 99% CI, 
−107.3 to 278.0 ng/mL; P =  .48; 18 hours: 384.7 ± 186.9 vs 
220.0 ± 52.4 ng/mL; 99% CI, −29.0 to 358.3 ng/mL; P = .04; 
24 hours: 448.9 ± 213.8 vs 277.5 ± 115.9 ng/mL; 99% CI, 
−22.2 to 365.1 ng/mL; P = .03; Figure 6A).
Figure 4. A–D, Pro- and anti-inflammatory mediators in bronchoalveolar lavage fluid (BALF). Assessment of the inflammatory response in the 
alveolar compartment by determination of proinflammatory cytokine such as monocyte chemoattractant protein-1 (MCP-1; A), cytokine-induced 
neutrophil chemoattractant-1 (CINC-1; B), interleukin-6 (IL-6; C), and the anti-inflammatory cytokine interleukin-10 (IL-10; D) in BALF from ven-
tilated rats subjected to acute lung injury by intratracheal lipopolysaccharide (LPS) application (control animals received phosphate-buffered 
saline [PBS]). Animals were sedated with propofol (-P) or sevoflurane (-S) for up to 24 hours. Values are expressed as mean ± SD. *P < .001 
LPS-P versus LPS-S at the corresponding time point.
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Plasma levels of CINC-1 at 6 hours after LPS challenge 
were also not different: LPS-P versus LPS-S: 6.7 ± 3.6 ver-
sus 4.8 ± 2.4 ng/mL; 99% CI, −0.4 to 4.2 ng/mL; P  =  .04 
(Figure 6B). IL-6 and IL-10 levels in plasma were below the 
detection range of the ELISA kit.
Hemodynamic Stability
Blood pressure was similar in all animal groups over time 
(Figure 7).
Continuous Ringer’s lactate application was evaluated 
in 30-minute intervals and was higher in the LPS-P versus 
the LPS-S group between 7.5 and 12.5 hours. The aver-
age fluid administered by continuous infusion within this 
period was 1.3 ± 0.1 versus 1.5 ± 0.2 mL/h. The following 
Dunnett-corrected P values for the 30-minute intervals were 
calculated: .037 (7.5–8 hours), .023 (8–8.5 hours), .024 (8.5–9 
hours), .036 (9–9.5 hours), .056 (9.5–10 hours), .037 (10–10.5 
hours), .037 (10.5–11 hours), .037 (11–11.5 hours), .023 (11.5–
12 hours), and .036 (12–12.5 hours). Also, between 6 and 
12 hours, cumulative application of Ringer’s lactate boluses 
was higher in the LPS-P compared with the LPS-S group 
(1.7 ± 0.7 vs 2.6 ± 1.4 mL; Dunnett-corrected P = .004).
Continuous norepinephrine infusions were not different 
between groups except for the first hour of treatment where 
the norepinephrine dosage was lower in LPS-P-treated 
 versus LPS-S-treated animals (0–30 minutes: 0.01 ± 0.03 vs 
0.09 ± 0.05; P = .006; 30–60 minutes: 0.05 ± 0.07 vs 0.14 ± 0.07 
μg/kg/min; Dunnett-corrected P < .001).
Renal Function
Overall fluid administration in animals treated for 24 hours 
was similar in all groups (PBS-P: 47.5 ± 4.8 mL; LPS-P: 51.2 
Figure 5. A–F, Pro- and anti-inflammatory mediators in lung tissue. Assessment of inflammation in the interstitial compartment by determina-
tion of messenger RNA of cytokines monocyte chemoattractant protein-1 (MCP-1; A), cytokine-induced neutrophil chemoattractant-1 (CINC-1; 
B), interleukin-6 (IL-6; C) and interleukin-12a (IL-12a; D), transforming growth factor-beta (TGF-β; E), and interleukin-10 (IL-10; F) in lung tissue 
from ventilated rats subjected to acute lung injury by intratracheal lipopolysaccharide (LPS) application (control animals received phosphate-
buffered saline [PBS]). Animals were sedated with propofol (-P) or sevoflurane (-S) for up to 24 hours. Values are expressed as mean ± SD. *P < .001 LPS-P versus LPS-S at the corresponding time point.
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± 4.2 mL; PBS-S: 51.0 ± 3.9 mL; LPS-S: 47.7 ± 4.2 mL; P = .55 
for LPS-P vs LPS-S). Overall fluid balance (fluid administra-
tion minus urine output) was not different between groups 
(Figure 8A).
Creatinine values in animals sedated for 24 hours in the 
LPS-P group did not differ from those in the LPS-S group (70 
± 59 vs 24 ± 11 μmol/L; 99% CI, −11 to 103 μmol/L; P = .05) 
or from either control groups (PBS-P: 37 ± 16 μmol/L; 99% 
CI, −97 to 31 μmol/L; P = .32, and PBS-S: 50 ± 36 μmol/L; 
99% CI, −43 to 84 μmol/L; P = .72; Figure 8B).
After 24 hours, urine NGAL was not different between 
groups (668 ± 473 μg/mL in LPS-P animals compared 
with 1756 ± 821 μg/mL in LPS-S animals; 99% CI, −2456 to 
278 μg/mL; P = .043; Figure 8C).
DISCUSSION
In this study, we found that rats with LPS-induced ALI had 
less biomarker evidence of inflammation, less histologic dam-
age to their lung, and less functional impairment of lung func-
tion when sedated with sevoflurane than with propofol.
Figure 6. A and B, Proinflammatory mediators in plasma. 
Determination of systemic inflammation by measurement of the pro-
inflammatory cytokines monocyte chemoattractant protein-1 (MCP-
1; A) and cytokine-induced neutrophil chemoattractant-1 (CINC-1; 
B) in plasma obtained from ventilated rats subjected to acute lung 
injury by intratracheal lipopolysaccharide (LPS) application; control 
animals received phosphate-buffered saline (PBS). Animals were 
sedated with propofol (-P) or sevoflurane (-S) for up to 24 hours. 
Values are expressed as mean ± SD.
Figure 7. Mean arterial blood pressure determined by a catheter 
in the right carotid artery in ventilated rats subjected to acute lung 
injury by intratracheal lipopolysaccharide (LPS) application (control 
animals received phosphate-buffered saline [PBS]). Animals were 
sedated with sevoflurane (-S) or propofol (-P) for up to 24 hours. 
Values are expressed as mean ± SD.
Figure 8. A–C, Renal parameters. Fluid balance after 24 hours (A) 
and renal parameters creatinine in blood (B) as well as neutrophil 
gelatinase-associated lipocalin, neutrophil gelatinase-associated 
lipocalin (NGAL; C) in urine derived from ventilated rats subjected to 
acute lung injury (ALI) by intratracheal lipopolysaccharide (LPS) appli-
cation (control animals received phosphate-buffered saline [PBS]). 
Animals were sedated with propofol (-P) or sevoflurane (-S) for up to 
24 hours. Data are expressed as box plots with mean ± maximum 
and minimum.
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Sedation and mechanical ventilation in the ICU is often 
required in patients experiencing ALI.25 Since the launch of 
the AnaConDa system, the use of sevoflurane and isoflu-
rane has become a more feasible option in Europe, but is 
still an off-label use in many countries, including the United 
States.26,27
The effect of sedation type on the course of ALI is 
unknown. In this study, we found improved oxygenation 
and an attenuated pulmonary inflammatory response when 
sevoflurane was used for sedation versus propofol.
When compared with propofol sedation, sevoflurane 
attenuated the production of proinflammatory cytokines 
IL-6, CINC-1, and reduced inflammatory cell counts in 
BALF. In lung tissue, representing the interstitial compart-
ment, mRNA of IL-6, CINC-1, and IL-12a was lower with 
sevoflurane than with propofol sedation. Similarly, in the 
vascular compartment, assessed by inflammatory media-
tors in the plasma, CINC-1 and MCP-1 were lower in ani-
mals sedated with sevoflurane, even not significant.
Our results are in accordance with several previous 
animal and clinical studies focusing on short-term volatile 
sedation or anesthesia. In a 2009 study, Voigtsberger et al12 
observed improved oxygenation and attenuated inflam-
matory response in an LPS-induced ALI rat model after 
6 hours when sevoflurane was used rather than propofol. 
Ferrando et al28 endorsed the results of Voigtsberger et al12 
in a porcine 2-hit ARDS model. In addition, the anti-inflam-
matory effects of volatile anesthetics in the deflated–reven-
tilated lung undergoing hypoxia–reoxygenation could 
also be verified in clinical investigations: De Conno et al29 
found that sevoflurane reduced pulmonary inflammatory 
response and chemoattraction of neutrophils in patients 
undergoing 1-lung ventilation for lung resection. Schilling 
et al30 described similar results for a sevoflurane or desflu-
rane anesthesia during 1-lung ventilation in the ventilated 
lung. In our study, we extended the duration of sedation 
to 24 hours, performed a more detailed investigation of the 
inflammation (in terms of time course and compartments), 
and supported blood pressure with norepinephrine to 
more closely simulate the ICU environment. Despite these 
changes, our results agree with those described earlier.
Of note is the only transient increased expression of pul-
monary cytokines. One possible explanation is that in the 
clinical environment, Gram-negative bacteria play a crucial 
role, whereas in our model, we used LPS instead of live 
bacteria. The advantage of our model is a greater degree 
of reproducibility, but a potential disadvantage may be a 
rapid removal of LPS leading to only a temporary inflam-
matory effect. The cytokine release patterns found in our 
experiments, however, have been previously described in 
humans.31 In an animal model of cecal ligation and puncture 
with vital bacteria as pathogens, a temporary upregulation 
of cytokines was observed as well.32
Another potential confounder in our study was the use 
of norepinephrine, which itself has immunomodulatory 
properties. Although norepinephrine doses were lower in 
the propofol group, the known pro- and anti-inflammatory 
effects of norepinephrine33 may have affected our results. 
However, the difference was only during the first hour, 
making a meaningful effect on the rest of the study unlikely.
The difference in norepinephrine application might 
be explained by different sedation techniques where we 
observed a slower onset of sedation in the propofol group 
because of different administration routes. Other investiga-
tors performing ICU studies have also reported that initial 
use of the AnaConDa may cause transient hypotension.34,35
We observed a distinct improvement in oxygenation 
in animals sedated with sevoflurane. This interesting and 
clinically relevant finding may be a result of an attenuated 
inflammation (as proven by the current study) and thus less 
pulmonary edema. The lower wet-to-dry ratio we found in 
the sevoflurane group, together with the results of a previ-
ous in vivo ALI study in which sevoflurane affected edema 
formation rather than clearance,36 supports this possibility. 
Beside an attenuation of inflammation, other factors may 
also contribute to an impaired oxygenation such as the 
development of atelectasis, which has been described in 
ventilated rats.37
For proper interpretation of the wet-to-dry ratio, hemo-
dynamic and fluid management have to be taken into con-
sideration. Fluid management was based on MAP, pulse 
pressure, urine output, and hematocrit. The LPS-P group 
received more fluid between 7.5 and 12 hours of sedation 
demonstrating an intergroup difference of 0.2 mL; although 
statistically significant, we consider this difference clinically 
not relevant. In addition, after 24 hours, overall fluid bal-
ance was similar between the 2 LPS groups.
The mechanism by which sevoflurane may affect pulmo-
nary edema or inflammation is unclear. However, 1 possible 
link is the pulmonary γ-aminobutyric acid type A (GABAA)-
receptor (GABAAR).38 Current studies suggest that modi-
fying or blocking GABAAR might lead to an improved 
alveolar fluid clearance in ALI39 and that GABAAR func-
tion may be modulated by isoflurane.39 Further work is 
needed to better understand the role of GABAAR in vola-
tile-mediated immunomodulation and alveolar fluid clear-
ance. Another potential mediator for the sevoflurane effect 
we observed is downregulation of toll-like receptor 2 and 
toll-like receptor 4 resulting in an attenuation of proinflam-
matory cytokines.40 Although not assessed in this current 
study, phosphorylation of extracellular-regulated kinase in 
macrophages on LPS stimulation may be another sevoflu-
rane-mediated immunomodulatory mechanism.41
In contrast to previous studies, we found that pulmo-
nary albumin content,12,42 another integrity marker of the 
alveolocapillary barrier, was not different between propofol 
and sevoflurane groups. This observation may be because 
of lower LPS doses used in our study compared with previ-
ous studies: our dose was adapted to provoke a moderate 
inflammatory response allowing for a 24-hour observation 
period without deaths because of sustained hemodynamic 
instability. The type and formulation of propofol may also 
have played a role: Voigtsberger et al12 used Cremophor as 
the pharmacologic carrier of propofol, whereas we used 1% 
propofol without ethylenediaminetetraacetic acid.
Volatile anesthetics exert a dose-dependent immuno-
modulation.40,41 In our study, however, we targeted a sevo-
flurane dose that mimics long-term sedation in the ICU. For 
that, 0.5 minimal alveolar concentration sevoflurane is suffi-
cient.34,43 This dose may be too low, however, to demonstrate 
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pronounced effects on neutrophil and alveolocapillary bar-
rier function as observed in previous studies.41,42
To our knowledge, our investigation is the first to dem-
onstrate a significant reduction of the proinflammatory 
cytokine IL-12a by sevoflurane. Dendritic cells, neutrophils, 
and mononuclear cells are the major source of IL-12. IL-12 
plays a pivotal role in the activation of natural killer cells 
and T-cells and the production of interferon-γ and other 
cytokines.44 Elimination of IL-12 may reduce mortality and 
attenuate bacterial count in sepsis.44 Further investigations 
will be needed to confirm whether or not an IL-12 reduction 
also leads to a survival benefit in ALI.
Because long-term sedation with sevoflurane may result 
in renal toxicity,20,22 we monitored renal function in our 
study using NGAL and creatinine. Although we found 
higher NGAL levels in sevoflurane-treated animals, creati-
nine levels were not different between groups. More work 
is needed to assess the potential nephrotoxicity of long-term 
sevoflurane sedation.
Our study has several limitations: (1) results from an ani-
mal model may not simply be translated/transferred into a 
clinical setting; (2) an observation period of 24 hours with 
volatile sedation may still be too short because patients 
experiencing ALI usually require a much longer duration of 
mechanical ventilation and sedation; (3) LPS leads to a ster-
ile infection, which may not reflect all aspects of a bacterial 
pulmonary infection; and (4) we adjusted ventilator settings 
during the experiment to achieve normoventilation, that is, 
normocapnia. In ALI and ARDS, permissive hypercapnia45,46 
is preferred over strict normoventilation, and hypercapnic 
acidosis may also affect inflammation and oxygenation.47,48
Avoidance of 1.0 Fio2, as performed in previous stud-
ies,12 may also have influenced the results because of the 
time-dependent impact of oxygen on pulmonary damage 
and mortality.49,50 We used a maximum Fio2 of 0.7, however, 
which is consistent with clinical care.
In summary, our study demonstrates that prolonged 
sedation with sevoflurane in the context of ALI attenuates 
the pulmonary inflammatory response, decreasing attraction 
of inflammatory cells into alveoli and decreasing production 
of proinflammatory cytokines. Our findings suggest that the 
attenaute pulmonary inflammation also results in less pul-
monary edema and improved oxygenation compared with 
propofol sedation. The current study is in accordance with 
previous short-term studies evaluating volatile sedation in 
the context of ALI. Further studies are needed to uncover 
possible mechanistic pathways involved in pulmonary pro-
tection and to address the question of transferability of our 
findings into a clinical setting. E
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